ID   PAX-C010
AC   CVCL_D7E5
DR   CCRID; 4201PAT-CCTCC00384
RX   Patent=CN102719403B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201074.
CC   Population: Chinese.
CC   Doubling time: 48.49 hours (Patent=CN102719403B).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): Patent=CN102719403B
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,11
ST   D16S539: 11,13
ST   D5S818: 10,11
ST   D7S820: 8,10
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C5721; Pancreatic adenosquamous carcinoma
DI   ORDO; Orphanet_424039; Squamous cell carcinoma of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   Patent=CN102719403B;
RA   Qin X.-R., Li F., Xie F.-B., Hu G., Wang K., Wen D.-Y., Zhu M.-H.,
RA   Zhang L.-Y., Jiang Z.-Z.;
RT   "A human pancreas adenosquamous carcinoma cell line and establishing
RT   method and application thereof.";
RL   Patent number CN102719403B, 20-Jan-2016.
//